Literature DB >> 26598387

Upfront combination therapy: does the AMBITION study herald a new era in the treatment of pulmonary arterial hypertension?

Steven D Nathan1, Paul A Corris2.   

Abstract

Entities:  

Keywords:  Primary Pulmonary Hypertension

Mesh：

Substances：

Year:  2015        PMID： 26598387     DOI： 10.1136/thoraxjnl-2015-207854

Source DB:  PubMed          Journal:  Thorax        ISSN： 0040-6376            Impact factor:   9.139


× No keyword cloud information.
  4 in total

Review 1.  A Contemporary Approach to Pulmonary Arterial Hypertension.

Authors:  Udhay Krishnan; Evelyn M Horn
Journal:  Curr Atheroscler Rep       Date:  2016-09       Impact factor: 5.113

Review 2.  Emerging application of genomics-guided therapeutics in personalized lung cancer treatment.

Authors:  Aubhishek Zaman; Trever G Bivona
Journal:  Ann Transl Med       Date:  2018-05

3.  Novel composite clinical endpoints and risk scores used in clinical trials in pulmonary arterial hypertension.

Authors:  Olivier Sitbon; Sylvia Nikkho; Raymond Benza; Chunqin Cq Deng; Harrison W Farber; Mardi G Maitland; Paul Hassoun; Christian Meier; Joanna Pepke-Zaba; Krishna Prasad; Werner Seeger; Paul A Corris
Journal:  Pulm Circ       Date:  2020-11-18       Impact factor: 3.017

4.  Assessment of the REPLACE study composite endpoint in riociguat-treated patients in the PATENT study.

Authors:  Gérald Simonneau; Hossein-Ardeschir Ghofrani; Paul A Corris; Stephan Rosenkranz; Ekkehard Grünig; Jim White; Vallerie V McLaughlin; David Langleben; Christian Meier; Dennis Busse; Frank Kleinjung; Raymond L Benza
Journal:  Pulm Circ       Date:  2020-12-09       Impact factor: 3.017
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.